The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis
Nephrology Dialysis Transplantation · 31.03.2026 · 41 (4) · 681-691
DOI: 10.1093/ndt/gfaf193 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 22.09.2025. Verfasst von Takaya Sasaki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Renal and Metabolic Division, George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Diabetes Mellitus, Type 2, Diabetic Nephropathies. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Heart Foundation Vanguard Grant, Royal Australasian College of Physicians Jacquot Research Establishment Fellowship, Uehara Memorial Foundation.
Abstract (Originalsprache)
Background and hypothesis Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are anti-hyperglycaemic agents, with cardioprotective effects, however their renal protective effects remain unclear. We aimed to assess the effects of GLP1-RAs on renal outcomes in patients with or without diabetes.
Methods
We performed a systematic review and meta-analysis with Medline, EMBASE and the Cochrane Register searched to December 2024. The primary outcome was the composite of kidney failure (defined as estimated glomerular filtration rate <15 mL/min/1.73 m2) or dialysis requirement, worsening of renal function and changes in proteinuria. Subgroup analysis was performed based on diabetic status, a (CKD) and individual GLP1-RA drugs. Relative risks (RR) with 95% confidence intervals (CI) for individual trials were pooled using random effects models.
Results
We identified 19 trials including 90 882 patients. Mean age was 60.8 years and mean follow-up was 25.9 months. GLP1-RAs were associated with a 19% reduction in the risk of primary renal outcome (RR 0.81, 95% CI 0.73–0.89), a 12% reduction in renal functional decline (RR 0.88, 95% CI 0.81–0.95) and a 0.45 mL/min/1.73 m2 reduction in yearly loss [16 trials, mean difference (MD) 0.45, 95% CI 0.10–0.81]. GLP1-RAs also reduced microalbuminuria by 24% (RR 0.76, 95% CI 0.71–0.82), HbA1c (units: %) by 0.61 (MD –0.61, 95% CI –0.76 to –0.49) and body weight by 5 kg (MD –5.24, 95% CI –7.46 to –3.02). Although there were no significant differences in progression to kidney failure (RR 0.86, 95% CI 0.71–1.05), GLP1-RAs reduced the incidence of major adverse cardiovascular events by 15% (RR 0.85, 95% CI 0.81–0.90) and all-cause mortality by 14% (RR 0.86, 95% CI 0.82–0.91). No significant differences were seen in severe adverse events (RR 0.96, 95% CI 0.90–1.01). However, there were more gastroenterological side effects.
Conclusions
GLP1-RAs demonstrated cardiovascular and renal benefits. Further high-quality randomized trials assessing their effects in patients without diabetes, with or without proteinuria and/or CKD are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal and Metabolic Division, George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
- Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Nephrology, Concord Repatriation General Hospital, Sydney, NSW, Australia.
- Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney, NSW, Australia.
- Department of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
- Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia.
ORCID-Profile: Takaya Sasaki, Rinaldo Bellomo
Förderung
- National Heart Foundation Vanguard Grant
- Royal Australasian College of Physicians Jacquot Research Establishment Fellowship
- Uehara Memorial Foundation
Zitieren
APA
Sasaki, T., Giang, S. M., Wu, J., Yokoo, T., Gallagher, M., Bellomo, R., & Wang, A. Y. (2026). The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 41(4), 681-691. https://doi.org/10.1093/ndt/gfaf193
Vancouver
Sasaki T, Giang SM, Wu J, Yokoo T, Gallagher M, Bellomo R, et al. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis. Nephrology Dialysis Transplantation. 2026;41(4):681-691. doi:10.1093/ndt/gfaf193
BibTeX
@article{Sasaki2026,
author = {Sasaki, Takaya and Giang, Samantha My-Linh and Wu, Jiajia and Yokoo, Takashi and Gallagher, Martin and Bellomo, Rinaldo and Wang, Amanda Ying},
title = {The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
volume = {41},
number = {4},
pages = {681--691},
doi = {10.1093/ndt/gfaf193}
}
EUVIMED